+Compare
BCLI
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
44.78M

BCLI Brainstorm Cell Therapeutics Forecast, Technical & Fundamental Analysis

a biotechnology company, which develops innovative adult stem cell therapeutic products

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BCLI with price predictions
08:00 PM EDT Sep 19, 2023

BCLI sees MACD Histogram just turned negative

BCLI saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 08, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 06, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on BCLI as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCLI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BCLI entered a downward trend on August 29, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCLI advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

BCLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (65.789) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (316.663).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BCLI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 22%, and the average quarterly price growth was 33%. BXPHF experienced the highest price growth at 300%, while SEEL experienced the biggest fall at -67%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was 29% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

BCLI is expected to report earnings to fall 44.44% to -15 cents per share on November 13

Brainstorm Cell Therapeutics BCLI Stock Earnings Reports
Q3'23
Est.
$-0.15
Q2'23
Missed
by $0.11
Q1'23
Beat
by $0.03
Q4'22
Missed
by $0.06
Q3'22
Missed
by $0.35
The last earnings report on August 14 showed earnings per share of -27 cents, missing the estimate of -15 cents. With 581.59K shares outstanding, the current market capitalization sits at 44.78M.
A.I. Advisor
published General Information

General Information

a biotechnology company, which develops innovative adult stem cell therapeutic products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Computer Peripherals
Address
1325 Avenue of Americas
Phone
+1 201 488-0460
Employees
43
Web
https://www.brainstorm-cell.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELV445.837.05
+1.61%
Elevance Health
OGN18.92-0.09
-0.47%
Organon & Co
SWIM2.55-0.04
-1.54%
Latham Group
STC44.94-0.95
-2.07%
Stewart Information Services Corp
REE0.15-0.01
-3.65%
REE Automotive Ltd

BCLI and

Correlation & Price change

A.I.dvisor tells us that BCLI and EQRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BCLI and EQRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-4.85%
EQRX - BCLI
31%
Poorly correlated
-1.32%
VERU - BCLI
29%
Poorly correlated
+11.01%
BLRX - BCLI
29%
Poorly correlated
-1.79%
ARCT - BCLI
27%
Poorly correlated
-4.88%
BMEA - BCLI
24%
Poorly correlated
-7.60%
More

Groups containing BCLI

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-4.85%
biotechnology
(undefined stocks)
10%
Poorly correlated
-1.79%
stem cells
(undefined stocks)
8%
Poorly correlated
+0.23%
therapeutics
(undefined stocks)
7%
Poorly correlated
-2.29%
computers
(undefined stocks)
2%
Poorly correlated
-0.65%